0.38
0.38 (-0.08%)
As of Feb 17, 2023
Perspective Therapeutics, Inc. [ISR]
Source:
Company Overview
Perspective Therapeutics, Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. We have proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
| Country | United States |
| Headquarters | seattle, washington |
| Phone Number | (206) 676-0900 |
| Industry | manufacturing |
| CEO | Johan (Thijs) Spoor |
| Website | www.perspectivetherapeutics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $1.5 |
| Operating Profit | $-90.9 |
| Net Income | $-79.3 |
| Net Cash | $52.2 |
Profit Ratios
| Gross Margin | $1.5 |
| Operating Margin | -6,250.8 |
| Profit as % of Revenues | -1.8% |
| Profit as % of Assets | -36.1% |
| Profit as % of Stockholder Equity | -27.3% |
Management Effectiveness
| Return on Equity | -27.3% |
| Return on Assets | -23.2% |
| Turnover Ratio | 0.7% |
| EBITA | $-90.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $341.1 |
| Total Liabilities | $50.4 |
| Operating Cash Flow | $-18.3 |
| Investing Cash Flow | $-218.9 |
| Financing Cash Flow | $289.4 |
